BCMA:APRIL[Biotinylated] Inhibitor Screening Assay Kit

Catalog #
79722
$765 *
Size: 96 Reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The BCMA:APRIL[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of BCMA:APRIL. The key to this kit is the high sensitivity of detection of biotin-labeled APRIL by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, BCMA is coated on a 96-well plate. Next, biotinylated APRIL is incubated with BCMA on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.

Synonyms
TNFRSF17, BCM, BCMA, CD269, TNFRSF13A, tumor necrosis factor receptor superfamily member 17, TNF receptor superfamily member 17
Product Info
Storage and Usage
Citations
Assay Kit Format
Chemiluminescent
Materials Required But Not Supplied

PBS (Phosphate buffered saline)
Luminometer or microplate reader capable of reading chemiluminescence
Adjustable micropipettor and sterile tips

Format
Catalog # Component Amount Storage
79465 BCMA, Fc-Fusion, Avi-Tag HiP™ 10 µg -80°C Avoid multiple
freeze/ thaw
cycles!
100262 APRIL, His-Avi-Tag, Biotin-Labeled 5 µg -80°C
79311 3x Immuno Buffer 1 50 ml -20°C
79728 Blocking Buffer 50 ml +4°C
79742 Streptavidin-HRP 15 µl -20°C
79670 ELISA ECL Substrate A 6 ml +4°C
ELISA ECL Substrate B 6 ml +4°C
79699 96-well white microplate 1 +4°C
UniProt #
BCMA: Q02223; APRIL: O75888
Background
A proliferation-inducing ligand (APRIL, TNSF13 or CD256) and B-cell maturation antigen (BCMA, also known as TNFRSF17 or CD269) create a signaling pathway that participates in the regulation of B-cell development, autoimmunity and long-term plasma cell survival. APRIL expression is significantly elevated in multiple myeloma (MM) and it has been demonstrated that activation of BCMA by APRIL promotes tumor growth, chemoresistance and immunosuppression in the bone marrow microenvironment. Anti-APRIL monoclonal antibodies have been recently progressed to clinical trials for MM.
References

1. Yu, G., et al. Nature Immunol. 2000, 1(3): 252
2. Tai Y, T., et al. Blood 2016, 127: 3225-3236.
3. Cho, S.-F., et al. Front. Immunol. 2018, 9:1821